Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2021/07/034664
CTRI/2021/07/034664Completed未知

Interleukin 6, serum ferritin and high-sensitivity C-reactive protein with severity of illness in patients with Covid-19.

Maulana Azad Medical College0 sites100 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
100
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Inclusion Criteria

  • •Patients with Covid-19 Positive status diagnosed by either RT-PCR or Rapid Antigen Test Kit.

Exclusion Criteria

  • •1. Patients on prior history of immunosuppressive therapy.
  • •2. Patients already started on steroid / Tocilizumab or any other novel immunosuppressive
  • •therapy after admission .
  • •3. Patients who already received convalescent plasma therapy.
  • •4. Patients with Pregnancy.

Investigators

Similar Trials

Not yet recruiting
Not Applicable
aboratory parameters in febrile seizures.
CTRI/2019/02/017559kasturba hospital
Completed
Not Applicable
A study to compare two different markers in detecting bacteraemia in children with febrile neutropenia
CTRI/2018/02/011985Katurba Medical College Manipal32
Recruiting
Not Applicable
Role of Serum Interleukin-6 in Predicting bacterial infection in adults
CTRI/2018/11/016384Roche Diagnostics India Pvt Ltd
Recruiting
Not Applicable
The role of serum interleukin-6 level in predicting the postoperative complications after ovarian cancer surgery
CTRI/2018/04/013162Dr Vibhavari Naik
Not yet recruiting
Not Applicable
CYTOKINES(INFLAMMATORY MARKERS) IN SEVERE AND MODERATE COVID 19 PATIENTS AND ITS RELATION WITH THE OUTCOMES
CTRI/2020/12/030082PAVULURI KRISHNA SWATHI
Association of levels of inflammatory... | Clinical Trial